source
- Flagship’s ProFound Therapeutics secures up to $35 M from Gates Foundation to discover preeclampsia drug targetsFlagship Pioneering’s ProFound Therapeutics has entered a new partnership with the Gates Foundation that could provide up to $35 million for research. The agreement includes an initial $20 million…
- BMS terminates Cellares partnership after cell therapy platform fails to meet Breyanzi production needs, prompting layoffsBristol Myers Squibb has ended its collaboration with manufacturing specialist Cellares after the Cell Shuttle system could not satisfy the requirements for producing the approved CAR‑T therapy Bre…BioSpace · 1d agoDealNegative